News | April 25, 2024
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Revenue from operations up 26% to Rs. 768 crores
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)